Mayo Medical Laboratories

Mayo Medical Laboratories said this week that it has begun offering mass spec-based serum thyroglobulin testing using SISCAPA technology.

The Mayo Medical Laboratories will now offer Sequenom's MaterniT21 Plus test to patients at high risk for fetal chromosome abnormalities.

BioTheranostics said this week that Mayo Clinic and Mayo Medical Laboratories will offer the company's CancerType ID molecular cancer classification test to aid in the management of patients with metastatic cancer.

NEW YORK (GenomeWeb News) – Mayo Clinic and Mayo Medical Laboratories will offer BioTheranostics' CancerType ID molecular cancer classification test under a deal announced today.

The new test will be based on real-time PCR using fluorescence resonance energy transfer probes for detection.

The technology will allow Mayo to offer a test for M. tuberculosis complex speciation.

The eventual goal of the partnership would be to port the validated assay onto Rheonix's fully automated, modular molecular testing platform, which is still under development but may reduce the complexity and cost of warfarin sensitivity testing.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.